Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.

Kaelo K Seatla; Ava Avalos; Sikhulile Moyo; Madisa Mine; Thabo Diphoko; Mosepele Mosepele; Tendani Gaolatlhe; Christopher F Rowley; Dinah Ramaabya; Joseph N Jarvis ORCID logo; +2 more... Ishmael Kasvosve; Simani Gaseitsiwe; (2018) Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana. AIDS (London, England), 32 (13). pp. 1899-1902. ISSN 0269-9370 DOI: 10.1097/QAD.0000000000001920
Copy

: There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.


picture_as_pdf
Four class drug resistant HIV_GREEN AAM.pdf
subject
Accepted Version
Available under Creative Commons: NC-ND 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads